FY2018 EPS Estimates for Exelixis, Inc. Lowered by William Blair (EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at William Blair reduced their FY2018 earnings per share estimates for shares of Exelixis in a report issued on Monday, October 15th, Zacks Investment Research reports. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of $0.94 per share for the year, down from their previous estimate of $1.00. William Blair also issued estimates for Exelixis’ FY2020 earnings at $1.18 EPS.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.19 by $0.22. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The company had revenue of $225.40 million for the quarter, compared to analyst estimates of $174.14 million. During the same period in the prior year, the company earned $0.26 earnings per share. The firm’s revenue was up 47.8% on a year-over-year basis.

EXEL has been the topic of several other reports. Oppenheimer set a $40.00 target price on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 1st. Goldman Sachs Group began coverage on shares of Exelixis in a research note on Monday, September 17th. They set a “neutral” rating and a $22.00 target price on the stock. BidaskClub raised shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. Stifel Nicolaus reduced their price target on shares of Exelixis from $29.00 to $25.00 and set a “hold” rating for the company in a research report on Wednesday, August 1st. Finally, Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 price objective for the company in a report on Tuesday, July 31st. Three analysts have rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Exelixis has an average rating of “Buy” and an average price target of $29.44.

Shares of EXEL stock traded down $0.45 during mid-day trading on Thursday, hitting $16.67. 4,233,603 shares of the stock were exchanged, compared to its average volume of 4,612,580. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01. Exelixis has a 52-week low of $13.42 and a 52-week high of $32.20. The firm has a market cap of $5.18 billion, a P/E ratio of 32.69, a PEG ratio of 1.03 and a beta of 2.29.

In other news, insider Gisela Schwab sold 12,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $17.77, for a total value of $213,240.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Morrissey sold 90,000 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $17.82, for a total transaction of $1,603,800.00. The disclosure for this sale can be found here. Insiders sold a total of 321,500 shares of company stock worth $5,646,160 over the last 90 days. Company insiders own 4.80% of the company’s stock.

A number of large investors have recently made changes to their positions in EXEL. Dimensional Fund Advisors LP raised its stake in Exelixis by 13.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,038,173 shares of the biotechnology company’s stock worth $22,996,000 after acquiring an additional 121,770 shares in the last quarter. Sei Investments Co. increased its stake in Exelixis by 61.0% in the first quarter. Sei Investments Co. now owns 62,457 shares of the biotechnology company’s stock valued at $1,383,000 after purchasing an additional 23,653 shares during the period. Asset Management One Co. Ltd. acquired a new position in Exelixis in the first quarter valued at $248,000. Principal Financial Group Inc. increased its stake in Exelixis by 5.1% in the first quarter. Principal Financial Group Inc. now owns 91,006 shares of the biotechnology company’s stock valued at $2,016,000 after purchasing an additional 4,445 shares during the period. Finally, UBS Group AG increased its stake in Exelixis by 162.5% in the first quarter. UBS Group AG now owns 393,116 shares of the biotechnology company’s stock valued at $8,707,000 after purchasing an additional 243,361 shares during the period. Hedge funds and other institutional investors own 81.84% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: Cash Flow

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply